{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:53:58Z","timestamp":1780480438380,"version":"3.54.1"},"reference-count":62,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2015,8,18]],"date-time":"2015-08-18T00:00:00Z","timestamp":1439856000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2015,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The antifolate agent methotrexate is routinely used for systemic therapy of cancer and chronic inflammatory diseases. Successful topical use has been described for individual therapeutic attempts, in case series, and small studies, especially for mycosis fungoides (premycotic stage) and lymphomatoid papulosis. With respect to its clinical use in selected treatment scenarios, there have been no approved preparations or regulated instructions for pharmaceutical compounding.<\/jats:p><\/jats:sec><jats:sec><jats:title>Material and methods<\/jats:title><jats:p>Two high performance liquid chromatography methods were established for the determination of the active substance within a galenic formulation as well as within extracts of biological material. Suitable vehicles for epicutaneous application were developed and preclinically tested for stability, release, and pharmacokinetics of the active substance as well as their safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The tests show that methotrexate may be readily incorporated into \u201cBasiscreme DAC\u201d. It remains stable up to a concentration of 0.5\u00a0%. This preparation releases enough active substance to achieve relevant local bioavailability in the respective target compartments of the skin. There is no evidence of safety risks due to relevant systemic bioavailability after topical application on a limited area of the skin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In summary, this approved prescription for extemporaneous preparation complies with the requirements of the German Ordinance on the Operation of Pharmacies (Article 7 ApBetrO), and the available data proves its stability and pharmaceutical quality.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ddg.12622","type":"journal-article","created":{"date-parts":[[2015,8,18]],"date-time":"2015-08-18T12:47:21Z","timestamp":1439902041000},"page":"891-901","source":"Crossref","is-referenced-by-count":10,"title":["Methotrexate for topical application in an extemporaneous preparation"],"prefix":"10.1111","volume":"13","author":[{"given":"Johannes","family":"Wohlrab","sequence":"first","affiliation":[{"name":"University Hospital for Dermatology and Venereology Martin Luther University Halle\u2010Wittenberg  Halle (Saale) Germany"},{"name":"Institute for Applied Dermopharmacology Martin Luther University Halle\u2010Wittenberg  Halle (Saale) Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard H.H.","family":"Neubert","sequence":"additional","affiliation":[{"name":"Institute for Applied Dermopharmacology Martin Luther University Halle\u2010Wittenberg  Halle (Saale) Germany"},{"name":"Institute for Pharmacy Martin Luther University Halle\u2010Wittenberg  Halle (Saale) Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Michael","sequence":"additional","affiliation":[{"name":"Institute for Applied Dermopharmacology Martin Luther University Halle\u2010Wittenberg  Halle (Saale) Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Naumann","sequence":"additional","affiliation":[{"name":"Institute for Pharmacy Martin Luther University Halle\u2010Wittenberg  Halle (Saale) Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,8,18]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-005-4541-1"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2012.07926_suppl.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1610-0387.2012.07899.x","article-title":"Therapy of severe atopic dermatitis in adults","volume":"10","author":"Deleuran MS","year":"2012","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_8_5_1","doi-asserted-by":"crossref","first-page":"457","DOI":"10.18388\/abp.1995_4899","article-title":"Molecular mechanisms of resistance to antifolates, a review","volume":"42","author":"Banerjee D","year":"1995","journal-title":"Acta Biochim Pol"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2004.09.001"},{"key":"e_1_2_8_7_1","unstructured":"FachInfo\u2010Service.Fachinformation Metex 7 5\u00a0mg\/10\u00a0mg Tabletten 2009."},{"key":"e_1_2_8_8_1","article-title":"Methotrexat Sandoz Infusionskonzentrat","author":"Fachinformation","year":"2010","journal-title":"Arzneimittel\u2010Kompendium der Schweiz"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350603"},{"key":"e_1_2_8_10_1","first-page":"S27","article-title":"Methotrexate bioavailability","volume":"28","author":"Roon EN","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-813426"},{"key":"e_1_2_8_12_1","first-page":"199","article-title":"Methotrexatbehandlung der chronischen Polyarthritis 1994 \u2013 Eine \u00dcbersicht","volume":"53","author":"Rau R","year":"1994","journal-title":"Z Rheumatol"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342020-00003"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199604000-00004"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/34.5.421"},{"key":"e_1_2_8_16_1","unstructured":"FachInfo\u2010Service.Fachinformation Methotrexat 5\u00a0000\u00a0mg Infusionsl\u00f6sung medac.2010."},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1993.tb04158.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050404"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600780219"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330620"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00546716"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(91)70199-C"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(03)00470-5"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.5.624"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2014.03.002"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1967.01610050005001"},{"key":"e_1_2_8_27_1","first-page":"669","article-title":"Clinical and histopathological evaluation of the topical treatment of psoriasis with methotrexate and locacorten tar","volume":"57","author":"Czernielewski A","year":"1970","journal-title":"Przegl Dermatol"},{"key":"e_1_2_8_28_1","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2340\/0001555566515519","article-title":"Topical treatment of psoriatic skin with methotrexate cream: a clinical, pharmacokinetic, and histological study","volume":"66","author":"Bjerring P","year":"1986","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1989.01670140079014"},{"key":"e_1_2_8_30_1","first-page":"270","article-title":"Topical methotrexate therapy in palmoplantar psoriasis","volume":"65","author":"Kumar RBC","year":"1999","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2003.01718.x"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2004.tb00602.x"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2006.02911.x"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06455.x"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.20655"},{"key":"e_1_2_8_36_1","first-page":"117","article-title":"Combination of calcipotriol and methotrexate in nanostructured lipid carriers for topical delivery","volume":"5","author":"Lin YK","year":"2010","journal-title":"Int J Nanomedicine"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2010.06.014"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12481444"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5173(00)00674-8"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5173(00)00599-8"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2001.01244.x"},{"key":"e_1_2_8_42_1","first-page":"103","article-title":"Methotrexate allergy","volume":"137","author":"Geggie PH","year":"1987","journal-title":"CMAJ"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1990.tb01604.x"},{"key":"e_1_2_8_44_1","first-page":"1320","article-title":"Methotrexate induced early onset pancytopenia in rheumatoid arthritis: drug allergy? Idiosyncrasy","volume":"19","author":"Tanaka Y","year":"1992","journal-title":"J Rheumatol"},{"key":"e_1_2_8_45_1","unstructured":"Rextop\u00ae Produktdarstellung http:\/\/www.medindia.net\/drugprice\/methotrexate\/rextop.htm access: 17.10.2014."},{"key":"e_1_2_8_46_1","unstructured":"U.S. National Institutes of Health ClinicalTrial.gov http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00666354?term= MediQuest&rank=10 access: 03.10.2014."},{"key":"e_1_2_8_47_1","unstructured":"Commitee for Medicinal Products for Human Use (CHMP). Guideline on bioanalytical method validation (version 21 July 2011).http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_ library\/Scientific_guideline\/2011\/08\/WC500109686.pdf access: 17.10.2014"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/pauz.19890180403"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12533356"},{"key":"e_1_2_8_50_1","unstructured":"OECD\/OCDE. OECD (428) Guideline for the testing of chemicals. Skin absorption: in vitro method 2004.http:\/\/www.oecd\u2010ilibrary.org\/docserver\/download\/9742701e.pdf? expires=1365075065&id=id&accname=guest&checksum=17EA2B94BD8400DC17F04BCCE29BCF64 access: 04.04.2013."},{"key":"e_1_2_8_51_1","unstructured":"OECD\/OCDE. Guidance document for the cinduct of skin absorption studies 2004.http:\/\/search.oecd.org\/officialdocuments\/displaydocumentpdf\/?doclanguage= en&cote=env\/jm\/mono(2004)2 access: 04.04.2013."},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1159\/000362740"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/0278-6915(85)90030-4"},{"key":"e_1_2_8_54_1","unstructured":"ICCVAM\u2010Recommended Test Method Protocol: Hen's Egg Test \u2013 Chorioallantoic Membrane (HET\u2010CAM) Test Method 10\u20137553 NPN 2010.http:\/\/ntp.niehs.nih.gov\/iccvam\/docs\/protocols\/ivocular\u2010hetcam.pdf access: 03.10.2014."},{"key":"e_1_2_8_55_1","unstructured":"ICH\u2010Guideline. Stability testing of new drug substances and products Q1A (r2) 2003.http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm073369.pdf access: 03.10.2014."},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2002.01621.x"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2005.pto960318.x"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1208\/ps040442"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.10432"},{"issue":"2","key":"e_1_2_8_60_1","first-page":"S1","article-title":"S3\u2010Leitlinie zur Therapie der Psoriasis vulgaris Update 2011","volume":"9","author":"Nast A","year":"2011","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.53.7.475"},{"key":"e_1_2_8_62_1","unstructured":"OckenfelsH\u2010M.Leitlinie zur Therapie der Psoriasis vulgaris. In:Sterry W: AWMF online 2011:127\u201336.http:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/013\u2010001l_S3_Psoriasis_vulgaris_ Therapie_01.pdf access: 03.10.2014."},{"key":"e_1_2_8_63_1","first-page":"1344","article-title":"A Study of Distribution of Methotrexate in Human Tissues and Tumors","volume":"30","author":"Anderson LL","year":"1970","journal-title":"Cancer Res"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fddg.12622","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.12622","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T03:34:21Z","timestamp":1696217661000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.12622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,18]]},"references-count":62,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["10.1111\/ddg.12622"],"URL":"https:\/\/doi.org\/10.1111\/ddg.12622","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,18]]}}}